Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neo-adjuvant Intratumoral Anti-CTLA4 + Anti-PD1 in Patients With Localized Melanoma

NCT07230613 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT07230613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07230613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neo-adjuvant Intratumoral Anti-CTLA4 + Anti-PD1 in Patients With Localized Melanoma
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Recruiting
Start date
January 12, 2026
Completion date
December 31, 2033
Enrollment
50 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma, stage iii, mucosal melanoma